BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 21299862)

  • 1. During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein.
    Salazar MD; Ratnam M; Patki M; Kisovic I; Trumbly R; Iman M; Ratnam M
    Breast Cancer Res; 2011 Feb; 13(1):R18. PubMed ID: 21299862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of estrogen receptor alpha, retinoic acid receptor alpha and cellular retinoic acid binding protein II genes is coordinately regulated in human breast cancer cells.
    Lu M; Mira-y-Lopez R; Nakajo S; Nakaya K; Jing Y
    Oncogene; 2005 Jun; 24(27):4362-9. PubMed ID: 15870697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer.
    Chung YL; Sheu ML; Yang SC; Lin CH; Yen SH
    Int J Cancer; 2002 Jan; 97(3):306-12. PubMed ID: 11774281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of retinoic acid receptor alpha is sufficient for full induction of retinoid responses in SK-BR-3 and T47D human breast cancer cells.
    Schneider SM; Offterdinger M; Huber H; Grunt TW
    Cancer Res; 2000 Oct; 60(19):5479-87. PubMed ID: 11034091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinoic acid receptor alpha expression correlates with retinoid-induced growth inhibition of human breast cancer cells regardless of estrogen receptor status.
    Fitzgerald P; Teng M; Chandraratna RA; Heyman RA; Allegretto EA
    Cancer Res; 1997 Jul; 57(13):2642-50. PubMed ID: 9205071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estradiol induction of retinoic acid receptors in human breast cancer cells.
    Roman SD; Ormandy CJ; Manning DL; Blamey RW; Nicholson RI; Sutherland RL; Clarke CL
    Cancer Res; 1993 Dec; 53(24):5940-5. PubMed ID: 8261407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
    Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
    J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The proapoptotic gene interferon regulatory factor-1 mediates the antiproliferative outcome of paired box 2 gene and tamoxifen.
    Wang S; Somisetty VS; Bai B; Chernukhin I; Niskanen H; Kaikkonen MU; Bellet M; Carroll JS; Hurtado A
    Oncogene; 2020 Oct; 39(40):6300-6312. PubMed ID: 32843722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells.
    Mai Z; Blackburn GL; Zhou JR
    Mol Carcinog; 2007 Jul; 46(7):534-42. PubMed ID: 17295235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular and molecular determinants of all-trans retinoic acid sensitivity in breast cancer: Luminal phenotype and RARα expression.
    Centritto F; Paroni G; Bolis M; Garattini SK; Kurosaki M; Barzago MM; Zanetti A; Fisher JN; Scott MF; Pattini L; Lupi M; Ubezio P; Piccotti F; Zambelli A; Rizzo P; Gianni' M; Fratelli M; Terao M; Garattini E
    EMBO Mol Med; 2015 Jul; 7(7):950-72. PubMed ID: 25888236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The N-terminal of the estrogen receptor (ERalpha) mediates transcriptional cross-talk with the retinoic acid receptor in human breast cancer cells.
    Rousseau C; Pettersson F; Couture MC; Paquin A; Galipeau J; Mader S; Miller WH
    J Steroid Biochem Mol Biol; 2003 Jul; 86(1):1-14. PubMed ID: 12943740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.
    Hutcheson IR; Knowlden JM; Madden TA; Barrow D; Gee JM; Wakeling AE; Nicholson RI
    Breast Cancer Res Treat; 2003 Sep; 81(1):81-93. PubMed ID: 14531500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations.
    Koay DC; Zerillo C; Narayan M; Harris LN; DiGiovanna MP
    Breast Cancer Res; 2010; 12(4):R62. PubMed ID: 20696059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA.
    Paroni G; Fratelli M; Gardini G; Bassano C; Flora M; Zanetti A; Guarnaccia V; Ubezio P; Centritto F; Terao M; Garattini E
    Oncogene; 2012 Jul; 31(29):3431-43. PubMed ID: 22056878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
    Osipo C; Gajdos C; Cheng D; Jordan VC
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
    Bergamaschi A; Christensen BL; Katzenellenbogen BS
    Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.
    Ikeda H; Taira N; Hara F; Fujita T; Yamamoto H; Soh J; Toyooka S; Nogami T; Shien T; Doihara H; Miyoshi S
    Breast Cancer Res; 2010; 12(3):R43. PubMed ID: 20579400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
    Creighton CJ; Massarweh S; Huang S; Tsimelzon A; Hilsenbeck SG; Osborne CK; Shou J; Malorni L; Schiff R
    Cancer Res; 2008 Sep; 68(18):7493-501. PubMed ID: 18794137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.